| Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study |
Completed |
Neoplasms |
NCT02636426 |
| Second Line Sorafenib After Pazopanib in Patients With RCC |
Terminated |
Metastatic Renal Cell Carcinoma |
NCT02122003 |
| Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer |
Withdrawn |
Hepatocellular Cancer |
NCT02288507 |
| Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma, Radiotherapy, Sorafenib |
NCT03535259 |
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma |
NCT02733809 |
| Sorafenib for Patients With Extensive Keloids |
Terminated |
Keloids |
NCT01425216 |
| Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection |
Terminated |
Hepatocellular Carcinoma|Recurrence |
NCT02867280 |
| Sorafenib for Hepatopulmonary Syndrome |
Terminated |
Hepatopulmonary Syndrome |
NCT02021929 |
| Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus |
Not yet recruiting |
Unresectable Hepatocellular Cancer|Portal Vein Tumor Thrombus |
NCT04069949 |
| Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study |
Completed |
Thyroid Cancer |
NCT02084732 |
| CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma|Advanced Cancer |
NCT03582618 |
| Trial of TRC105 and Sorafenib in Patients With HCC |
Completed |
Hepatocellular Carcinoma |
NCT02560779 |
| Phase â…ˇ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE |
Terminated |
Hepatocellular Carcinoma |
NCT03722498 |
| Sorafenib Chemoembolization Evaluation Controlled Trial |
Recruiting |
Hepatocellular Carcinoma |
NCT01906216 |
| Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer Metastatic |
NCT01471353 |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma |
Active, not recruiting |
Neuroblastoma |
NCT02298348 |
| Bioequivalence Study of Sorafenib Tablet and Nexavar |
Completed |
Fasting |
NCT02599337 |
| Sorafenib PK in Patients With Advanced HCC and Child-Pugh B |
Terminated |
BCLC Stage C HCC|CP-B Liver Cirrhosis |
NCT04051853 |
| Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma |
Unknown status |
PHENYTOIN/SORAFENIB [VA Drug Interaction]|Liver Neoplasms|Carcinoma, Hepatocellular|Digestive System Neoplasms|Neoplasms by Site|Liver Diseases|Adenocarcinoma|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]|HBV |
NCT01556815 |
| Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT01203787 |
| Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer |
Completed |
Hepatocellular Cancer|Liver Cancer |
NCT02069145 |
| Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML |
Completed |
Acute Myeloid Leukemia|Hematopoietic Stem Cell Transplantation |
NCT02474290 |
| Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) |
Terminated |
Chronic Lymphocytic Leukemia |
NCT01510756 |
| Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) |
Unknown status |
Hepatocellular Carcinoma|Metastasis |
NCT02311205 |
| Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT01507064 |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome |
Completed |
Leukemia |
NCT01254890 |
| A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients |
Completed |
T Cell Lymphoma |
NCT01561833 |
| Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia |
Completed |
Leukemia|Acute Myeloid Leukemia |
NCT02530476 |
| Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases |
Unknown status |
Metastatic Renal Cell Carcinoma |
NCT01444807 |
| Sorafenib Drug Drug Interaction Study in Healthy Male Subjects |
Completed |
Drug Interactions |
NCT02332031 |
| Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas |
Terminated |
neurofibromatosis1 (NF1)|Recurrent or Progressive Optic Pathway Gliomas (OPG)|Recurrent or Progressive Low-grade Glioma |
NCT01338857 |
| Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00780169 |
| Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma|Face Cancer |
NCT01833299 |
| Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients |
Completed |
Hepatocellular Cancer |
NCT00997022 |
| Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma |
Terminated |
Metastatic Renal Cell Carcinoma |
NCT01342627 |
| Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors |
Withdrawn |
Refractory Solid Tumors |
NCT02691780 |
| Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) |
Completed |
Leukemia, Myeloid, Acute|Leukemia, Promyelocytic, Acute|Myelodysplastic Syndromes |
NCT00875745 |
| Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) |
Completed |
Renal Cell Carcinoma |
NCT00478114 |
| Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT00846131 |
| Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant |
Completed |
Acute Myeloid Leukemia |
NCT01398501 |
| Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma (HCC) |
NCT02834546 |
| Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) |
Recruiting |
Hepatocellular Carcinoma |
NCT03606590 |
| Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma |
Unknown status |
Advanced Hepatocellular Carcinoma |
NCT02150317 |
| A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer |
Terminated |
Liver Cancer |
NCT01334710 |
| AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma |
NCT01029418 |
| Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma |
Unknown status |
Hepatocellular Carcinoma |
NCT01328223 |
| Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma |
Withdrawn |
Medullary Thyroid Carcinoma |
NCT01736878 |
| SORAVE - Sorafenib and Everolimus in Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific|Non-Small Cell Lung Cancer |
NCT00933777 |
| TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma |
NCT02529761 |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation |
Completed |
Leukemia |
NCT02196857 |
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
Recruiting |
Advanced Hepatocellular Carcinoma |
NCT04000737 |
| Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer |
Completed |
Carcinoma, Non Small Cell Lung |
NCT00954278 |
| Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail |
Completed |
Hepatocellular Carcinoma |
NCT02961998 |
| Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer |
Terminated |
Hereditary Clear Cell Renal Cell Carcinoma|Kidney Cancer |
NCT00727532 |
| Relative Bioavailability of Sorafenib Tablet for Oral Suspension |
Completed |
Biological Availability |
NCT02538393 |
| Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC |
Terminated |
Non Squamous Cell Lung Cancer|Non Small Cell Lung Cancer |
NCT00801801 |
| Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent |
Completed |
Bladder Cancer |
NCT00544609 |
| Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) |
Withdrawn |
Hepatocellular Carcinoma |
NCT00808145 |
| Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer |
Active, not recruiting |
Thyroid Cancer |
NCT01141309 |
| Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone |
Active, not recruiting |
Hepatocellular Carcinoma (HCC) |
NCT02562755 |
| Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD |
Recruiting |
AML|FLT3-ITD Mutation |
NCT03170895 |
| Sorafenib and TRC105 in Hepatocellular Cancer |
Completed |
Hepatoma|Liver Neoplasms|Adenoma, Liver Cell|Carcinoma, Hepatocellular|Liver Neoplasms, Experimental |
NCT01306058 |
| Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) |
Unknown status |
Kidney Cancer|Liver Cancer |
NCT01230697 |
| Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer |
Terminated |
Prostate Cancer |
NCT00924807 |
| Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer |
Recruiting |
Hepatocellular Cancer |
NCT03037437 |
| Combined Radiotherapy and Sorafenib in Patients With Hepatoma |
Unknown status |
Hepatocellular Carcinoma |
NCT01319942 |
| Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00647426 |
| Sorafenib in Treating Patients With Advanced Malignant Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00810394 |
| Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal |
Completed |
Renal Cell Carcinoma|Metastatic Disease |
NCT00480389 |
| Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer |
Completed |
Carcinoma, Renal Cell|Kidney Disease|Kidney Cancer |
NCT00854620 |
| Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib |
Recruiting |
Thyroid Carcinoma |
NCT02185560 |
| Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer |
Completed |
Thyroid Cancer |
NCT01025453 |
| A Study of Radiation With Sorafenib in Advanced Cancer |
Completed |
Cancer |
NCT00610246 |
| Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE |
Terminated |
Advanced Hepatocellular Carcinoma |
NCT01539018 |
| Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT00956436 |
| Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Carcinoma, Hepatocellular |
NCT00703365 |
| Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT00892658 |
| Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer |
Completed |
Esophageal Cancer|Gastroesophageal Junction Cancer |
NCT00917462 |
| Metformin Plus Sorafenib for Advanced HCC |
Unknown status |
Hepatocellular Carcinoma |
NCT02672488 |
| Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma |
Completed |
Thyroid Cancer |
NCT00887107 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer |
Terminated |
Kidney Cancer |
NCT00496756 |
| Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery |
Terminated |
Sarcoma |
NCT00880542 |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer |
Terminated |
Carcinoma, Hepatocellular |
NCT02323906 |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors |
Completed |
Neuroendocrine Tumor|Carcinoid Tumor|Pancreatic Neuroendocrine Tumor |
NCT00942682 |
| A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma |
Unknown status |
Renal Cell Carcinoma |
NCT01041482 |
| Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Hepatocellular Carcinoma|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Childhood Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma |
NCT02072486 |
| Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma|Liver Cancer |
NCT01005875 |
| Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. |
Completed |
HCC |
NCT02971696 |
| Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer |
Unknown status |
Hepatocellular Cancer |
NCT00813293 |
| Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma |
Completed |
Metastatic Osteosarcoma|Relapsed Osteosarcoma |
NCT01804374 |
| Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) |
Terminated |
Hepatocellular Carcinoma |
NCT00862082 |
| Depocyt® With Sorafenib in Neoplastic Meningitis |
Terminated |
Neoplastic Meningitis |
NCT00964743 |
| Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age |
Completed |
Acute Myeloid Leukemia (AML) |
NCT00893373 |
| Sorafenib in Newly Diagnosed High Grade Glioma |
Completed |
Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma |
NCT00884416 |
| Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) |
Completed |
Renal Cell Carcinoma |
NCT01613846 |
| Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC |
Unknown status |
Hepatocellular Carcinoma |
NCT01259193 |
| Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer |
Completed |
Liver Cancer |
NCT01075113 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma |
Withdrawn |
Melanoma|Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma |
NCT01851408 |
| Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors |
Completed |
SOLID TUMORS |
NCT00572078 |
| Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors |
Completed |
Brain Metastases|Primary Brain Tumors |
NCT00639262 |
| Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT04143191 |
| TACE Plus Sorafenib Versus TACE Alone for Recurrent Unresectable Hepatocellular Carcinoma |
Not yet recruiting |
Hepatocellular Carcinoma|Sorafenib|Transarterial Chemoembolization |
NCT04103398 |
| Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma |
Withdrawn |
Advanced Hepatocellular Carcinoma |
NCT02227914 |
| Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) |
Active, not recruiting |
Carcinoma, Hepatocellular|Secondary |
NCT02716766 |
| Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors |
Completed |
Metastatic Breast Cancer|Gastrointestinal Tumors |
NCT01640665 |
| Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion |
Completed |
Hepatocellular Carcinoma |
NCT01901692 |
| The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors |
Completed |
Solid Tumors |
NCT00984425 |
| Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00754923 |
| Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma |
NCT01032850 |
| Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors |
Completed |
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma |
NCT00703638 |
| Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer |
Recruiting |
Thyroid Cancer, Anaplastic |
NCT03565536 |
| Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00870532 |
| Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients |
Unknown status |
Metastatic Renal Cell Carcinoma |
NCT02330783 |
| Sorafenib-RT Treatment for Liver Metastasis (SLIM) |
Active, not recruiting |
Liver Metastasis|Cancer |
NCT00892424 |
| Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma |
Completed |
Liver Cancer |
NCT01932385 |
| Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy |
Completed |
Hepatocellular Carcinoma |
NCT01539681 |
| Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors |
Completed |
Refractory or Relapsed Solid Tumors |
NCT01634893 |
| Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer |
Completed |
Metastatic Differentiated Thyroid Cancer|Metastatic Poorly Differentiated Thyroid Cancer|Metastatic Anaplastic Thyroid Cancer|Metastatic Medullary Thyroid Cancer |
NCT00654238 |
| Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma |
Completed |
Renal Cell Carcinoma |
NCT01762150 |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM |
Completed |
Recurrent Glioblastoma Multiforme |
NCT00597493 |
| Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy |
Terminated |
Small Cell Lung Cancer |
NCT01159327 |
| A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01171651 |
| Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone |
Active, not recruiting |
Differentiated Thyroid Cancer |
NCT01263951 |
| Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma |
Completed |
Ocular Melanoma |
NCT01893099 |
| Study of Sorafenib/Cetuximab in Head and Neck Cancer |
Completed |
Squamous Cell Cancer |
NCT00815295 |
| Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT00764972 |
| Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis |
Terminated |
Liver Cancer |
NCT00767468 |
| A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02279719 |
| Sorafenib in Resected Non-small Cell Lung Carcinoma |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00532025 |
| A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis |
Unknown status |
Portal Vein Tumor Thrombus |
NCT03178656 |
| Sorafenib Long Term Extension Program |
Active, not recruiting |
Neoplasms |
NCT00625378 |
| Pilot Study of Effect of Sorafenib on Portal Pressure |
Completed |
Clinically Significant Portal Hypertension |
NCT01714609 |
| A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion |
Not yet recruiting |
Hepatocellular Cancer |
NCT03971201 |
| Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02504983 |
| Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma |
Unknown status |
Metastatic Renal Cell Carcinoma |
NCT01481870 |
| Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors |
Completed |
Neuroendocrine Tumors |
NCT00605566 |
| Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer |
Completed |
Pancreatic Cancer|Adenocarcinoma of the Pancreas |
NCT00375310 |
| Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer |
Active, not recruiting |
Hereditary Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7 |
NCT00390325 |
| Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC |
Withdrawn |
Hepatocellular Carcinoma (HCC) |
NCT02406508 |
| Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT02425605 |
| Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer |
Terminated |
Breast Cancer |
NCT00525161 |
| Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine |
Completed |
Melanoma Stage III or IV|No Prior Chemotherapy |
NCT00794235 |
| Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC |
Completed |
Hepatocellular Carcinoma |
NCT02774187 |
| Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00622466 |
| Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma |
NCT02748304 |
| Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00543335 |
| Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation |
Recruiting |
HCC |
NCT04232722 |
| Sorafenib for Imatinib/Sunitinib-failed GIST |
Completed |
Gastrointestinal Stromal Tumors |
NCT01091207 |
| Sorafenib VS TACE in HCC Patients With Portal Vein Invasion |
Terminated |
Hepatocellular Carcinoma |
NCT01480817 |
| Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor |
Completed |
Non-Small Cell Lung Cancer |
NCT00922584 |
| Urea Cream Treatment Sorafenib-Associated HSFR in HCC |
Completed |
Hepatocellular Carcinoma |
NCT01934829 |
| Fingerprint Characterization of Sorafenib Treated HCC |
Recruiting |
Hepatocellular Carcinoma|Sorafenib |
NCT03958669 |
| Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma |
Unknown status |
Soft Tissue Sarcoma |
NCT00541840 |
| Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer |
Completed |
Carcinoma, Renal Cell |
NCT00445042 |
| Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma |
Withdrawn |
Hepatocellular Carcinoma|Hepatocellular Cancer|Hepatoma|Liver Cancer |
NCT01618253 |
| Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT00768937 |
| Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan |
Withdrawn |
Pediatric Solid Tumors |
NCT02747537 |
| Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer |
Completed |
Breast Cancer |
NCT00548899 |
| E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT01271504 |
| HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) |
Terminated |
Hepatocellular Cancer |
NCT01849588 |
| Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT00827177 |
| TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma |
Unknown status |
PHENYTOIN/SORAFENIB [VA Drug Interaction]|Carcinoma, Hepatocellular |
NCT01605734 |
| Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy |
Completed |
Hepatocellular Carcinoma |
NCT00933816 |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC |
Unknown status |
Advanced Hepatocellular Carcinoma|Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Neoplasms |
NCT01214343 |
| Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies |
Completed |
Solid Tumor |
NCT01683149 |
| Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall |
Completed |
Soft Tissue Sarcoma |
NCT00864032 |
| Combined Treatment of RFA and Sorafenib on Recurrent HCC |
Unknown status |
HCC|Radiofrequency Ablation|Sorafenib |
NCT01470495 |
| Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets |
Suspended |
Advanced Solid Tumors |
NCT01226056 |
| Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer |
Completed |
Rectal Cancer |
NCT01376453 |
| Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) |
Active, not recruiting |
Breast Cancer|Brain Metastases |
NCT01724606 |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer |
Completed |
Renal Cell Cancer |
NCT01189370 |
| Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma |
Terminated |
Metastatic Renal Cell Carcinoma |
NCT01100242 |
| Sorafenib/Docetaxel Dose Escalation Trial |
Completed |
Neoplasms |
NCT00562523 |
| Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. |
Terminated |
Carcinoma, Renal Cell |
NCT00622479 |
| 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer |
Active, not recruiting |
Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer |
NCT02624700 |
| A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT02358395 |
| Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy |
Unknown status |
Testicular Cancer |
NCT00772694 |
| Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer |
Active, not recruiting |
Hepatocellular Cancer|Liver Cancer |
NCT02292173 |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations |
Completed |
Acute Myelogenous Leukemia|Leukemia |
NCT00943943 |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma|Hepatoma |
NCT00844883 |
| Sorafenib in Myelodysplastic Syndrome |
Terminated |
Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic |
NCT00510289 |
| RDEA119 and Sorafenib Combination Dose Escalation Study |
Completed |
Advanced Cancer |
NCT00785226 |
| Sorafenib in Hormone NaĂŻve Biochemical Recurrence of Prostate Cancer |
Withdrawn |
Prostate Cancer |
NCT00694291 |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers |
Completed |
Renal Cancer|Non Small Cell Lung Cancer (NSCLC)|Soft Tissue Sarcoma |
NCT01005797 |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma |
Completed |
Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor |
NCT00837148 |
| Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype |
Completed |
Acute Myeloid Leukemia |
NCT01534260 |
| Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib |
Completed |
Non-Small Cell Lung Cancer |
NCT00609804 |
| Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients |
Completed |
Hepatocellular Carcinoma |
NCT01098760 |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT01008917 |
| Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection |
Unknown status |
Hepatocellular Carcinoma |
NCT02537158 |
| A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma |
Completed |
Advanced Renal Cell Carcinoma |
NCT01030783 |
| Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer |
Active, not recruiting |
Refractory Hurthle Cell Thyroid Cancer |
NCT02143726 |
| Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT02259647 |
| Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02642913 |
| Sorafenib Dose Escalation in Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT00618982 |
| Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia |
Active, not recruiting |
Acute Myeloid Leukemia With FLT3/ITD Mutation |
NCT01578109 |
| Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib |
Unknown status |
Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasm |
NCT01217034 |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC |
Terminated |
Carcinoma, Hepatocellular |
NCT00576056 |
| Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer |
Recruiting |
Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8 |
NCT03439891 |
| A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) |
Withdrawn |
Hepatocellular Carcinoma |
NCT01801163 |
| A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer |
Terminated |
Cholangiocarcinoma|Biliary Tract Cancer|Gallbladder Cancer |
NCT00955721 |
| Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer |
Completed |
Liver Cancer |
NCT01005199 |
| Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer |
Unknown status |
Hepatocellular Carcinoma |
NCT00999843 |
| EVESOR: a Phase 1 Trial of Everolimus and Sorafenib |
Unknown status |
Metastatic or Locally Advanced Solid Tumors |
NCT01932177 |
| Sorafenib Plus S-1 in Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT01128998 |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Advanced Hepatocellular Carcinoma |
NCT00882869 |
| Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC |
Active, not recruiting |
Hepatocellular Carcinoma (HCC) |
NCT03412773 |
| Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis |
Recruiting |
Hepatocellular Carcinoma|Metastasis |
NCT03518502 |
| TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) |
Terminated |
Hepatocellular Carcinoma |
NCT00618384 |
| Study of Curcumin, Vorinostat, and Sorafenib |
Withdrawn |
Advanced Cancers |
NCT01608139 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma |
Active, not recruiting |
Advanced Malignant Solid Neoplasm|Recurrent Melanoma|Refractory Malignant Solid Neoplasm|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7 |
NCT01303341 |
| Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) |
Unknown status |
Hepatocellular Carcinoma |
NCT00844688 |
| A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma |
Completed |
Advanced Solid Tumors|Hepatocellular Carcinoma |
NCT02354898 |
| Phase I Study of Vorinostat and Sorafenib in Advanced Cancer |
Completed |
Malignant Solid Tumour|Renal Cell Carcinoma|Non Small Cell Lung Carcinoma |
NCT00635791 |
| Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas |
Recruiting |
Brain Tumor|Glioblastoma|Anaplastic Glioma |
NCT01434602 |
| Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors |
Completed |
Refractory Solid Tumors |
NCT02450149 |
| A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC |
Active, not recruiting |
Carcinoma, Renal Cell |
NCT02627963 |
| Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer |
Completed |
Prostate Cancer |
NCT00414388 |
| MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma|Liver Cancer|HCC |
NCT02575339 |
| Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone |
Completed |
Renal Cell Carcinoma |
NCT00609934 |
| Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab |
Completed |
Kidney Cancer |
NCT00866320 |
| Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) |
Completed |
Carcinoma, Renal Cell |
NCT00586105 |
| Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) |
Completed |
Carcinoma, Hepatocellular |
NCT01915602 |
| PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors |
Completed |
Refractory Solid Tumors |
NCT00759928 |
| Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE |
Completed |
Malignant Neoplasm of Stomach|Effects of Chemotherapy |
NCT01187212 |
| Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) |
Terminated |
Carcinoma, Hepatocellular |
NCT01337492 |
| Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma |
Unknown status |
HCC |
NCT03097848 |
| Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors |
Completed |
Neoplasms |
NCT00606125 |
| Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC |
Unknown status |
HCC |
NCT02187081 |
| Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer |
Recruiting |
Advanced Adult Hepatocellular Carcinoma|Child-Pugh Class A|Stage III Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma |
NCT03211416 |
| An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301) |
Completed |
Advanced Renal Cell Carcinoma |
NCT01076010 |
| Activity of Sorafenib in Salivary Gland Cancer |
Completed |
Salivary Gland Cancer |
NCT01703455 |
| Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin |
Completed |
Cancer |
NCT00562913 |
| Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer |
Terminated |
Gastric Cancer |
NCT00595985 |
| Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors |
Completed |
Refractory Malignancy |
NCT00613145 |
| Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer |
Completed |
Kidney Cancer |
NCT00392821 |
| Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis |
Active, not recruiting |
Desmoid-Type Fibromatosis |
NCT02066181 |
| Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment |
Unknown status |
Colorectal Neoplasms |
NCT00839111 |
| A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). |
Completed |
Carcinoma|Non-Small-Cell Lung |
NCT00863746 |
| Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00825734 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract |
Completed |
Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer |
NCT01844947 |
| Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naĂŻve Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
Terminated |
Bladder Cancer|URINARY BLADDER |
NCT00714948 |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer |
Completed |
Ovarian Neoplasm|Fallopian Tube Cancer|Primary Peritoneal Cancer |
NCT00436215 |
| Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01258608 |
| Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer |
Recruiting |
Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer |
NCT01730937 |
| 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT00943449 |
| Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT01982097 |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia |
Completed |
Blastic Phase|Childhood Acute Promyelocytic Leukemia With PML-RARA|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Solid Neoplasm|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Juvenile Myelomonocytic Leukemia|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Disease |
NCT01445080 |
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer |
Completed |
Prostate Cancer |
NCT00090545 |
| Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma |
Terminated |
Renal Cell Carcinoma |
NCT00557830 |
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer |
Terminated |
Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer |
NCT00126568 |
| Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT01290926 |
| Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients |
Completed |
Thyroid Carcinoma |
NCT02114658 |
| Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis |
Unknown status |
HepatoCellular Carcinoma|Portal Vein Thrombosis |
NCT03009461 |
| BATTLE Program: Sorafenib in Patients With NSCLC |
Completed |
Lung Cancer |
NCT00411671 |
| Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma |
Withdrawn |
HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer |
NCT02989870 |
| Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors |
Completed |
Rhabdomyosarcoma and Other Soft Tissue Sarcomas|Ewing's Sarcoma Family of Tumors|Osteosarcoma|Neuroblastoma|Brain Tumors |
NCT01518413 |
| Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma |
Completed |
Metastatic Renal Cell Carcinoma |
NCT00848640 |
| Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia |
Active, not recruiting |
Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia |
NCT01861314 |
| Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma |
Completed |
Bladder Cancer |
NCT00461851 |
| Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan |
Completed |
Carcinoma, Renal Cell |
NCT01411423 |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02988440 |
| Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT01135056 |
| Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program |
Completed |
Carcinoma, Renal Cell |
NCT01412671 |
| Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria |
Unknown status |
Carcinoma, Hepatocellular |
NCT01141478 |
| Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT01840592 |
| Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma |
Completed |
Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor |
NCT00093613 |
| Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery |
Completed |
Kidney Cancer|Liver Cancer |
NCT01497444 |
| Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT00712790 |
| Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China |
Completed |
Carcinoma, Hepatocellular |
NCT01839630 |
| Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 |
Completed |
Clear Cell Renal Cell Carcinoma |
NCT00602862 |
| Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial |
Unknown status |
Liver Carcinoma |
NCT01272557 |
| Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer |
Completed |
Kidney Cancer |
NCT00405366 |
| Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML |
Completed |
Acute Myeloid Leukemia |
NCT00373373 |
| Sorafenib in Relapsed High Grade Osteosarcoma |
Completed |
Osteosarcoma |
NCT00889057 |
| Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
Completed |
Advanced Adult Hepatocellular Carcinoma |
NCT02024087 |
| Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy |
Terminated |
Breast Cancer |
NCT00722072 |
| Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer |
Unknown status |
Non-Small Cell Lung Cancer |
NCT00722969 |
| Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination |
Completed |
Neoplasms |
NCT01585870 |
| Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors |
Completed |
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors |
NCT01715441 |
| Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan |
Completed |
Carcinoma, Hepatocellular |
NCT01411436 |
| Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT01047891 |
| Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment |
Terminated |
Hepatocellular Carcinoma |
NCT03644511 |
| Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00064350 |
| Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor |
NCT01450384 |
| CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer |
Completed |
Advanced Hepatocellular Carcinoma|Liver Cancer|Hepatic Cancer|Liver Neoplasms |
NCT01033240 |
| Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma |
Terminated |
Glioblastoma|Gliosarcoma |
NCT00734526 |
| Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma |
Completed |
Renal Cancer|Melanoma |
NCT00418496 |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) |
Completed |
AML|Acute Myeloid Leukemia|Myelodysplastic Disorders |
NCT00542971 |
| A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer |
Completed |
Cancer of the Cervix |
NCT00510250 |
| Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib |
Completed |
Carcinoma, Hepatocellular |
NCT01933945 |
| The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer |
Terminated |
Esophageal Cancer |
NCT00619242 |
| Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer |
Completed |
Hepatocellular Carcinoma |
NCT01126645 |
| Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer |
Terminated |
Breast Cancer |
NCT01194869 |
| DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC |
Terminated |
Hepatocellular Carcinoma |
NCT01806740 |
| Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer |
Completed |
Small Cell Carcinoma|Lung Cancer |
NCT00466232 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma |
Completed |
Extrahepatic Bile Duct Adenocarcinoma|Gallbladder Adenocarcinoma|Gallbladder Adenocarcinoma With Squamous Metaplasia|Hilar Cholangiocarcinoma|Recurrent Extrahepatic Bile Duct Carcinoma|Recurrent Gallbladder Carcinoma|Undifferentiated Gallbladder Carcinoma|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma |
NCT01093222 |
| A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer. |
Terminated |
Carcinoma, Renal Cell |
NCT00678288 |
| Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) |
Withdrawn |
Hepatocellular Carcinoma |
NCT01335074 |
| A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Carcinoma, Non-Small Cell Lung |
NCT00300885 |
| Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma |
Completed |
Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma |
NCT00131937 |
| Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting |
Completed |
Carcinoma, Renal Cell |
NCT01557127 |
| Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant |
Completed |
Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer |
NCT00844168 |
| Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma |
Completed |
Child-Pugh A Hepatocellular Carcinoma |
NCT01903694 |
| SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma |
Completed |
Liver Carcinoma |
NCT01482442 |
| Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) |
Terminated |
Hepatocellular Carcinoma |
NCT00971126 |
| Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT00634634 |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma |
Completed |
Metastatic Renal Cell Carcinoma |
NCT01223027 |
| Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer |
Terminated |
Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer |
NCT00126659 |
| An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma |
Completed |
Melanoma |
NCT01078961 |
| Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying Fms-related Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) |
Recruiting |
FLT3-ITD Mutation|AML |
NCT03622541 |
| A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer |
Terminated |
Metastatic Colorectal Cancer |
NCT00779311 |
| Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP |
Completed |
Advanced Gastric Cancer |
NCT00565370 |
| Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia |
Completed |
Refractory Solid Tumors|Leukemia |
NCT00665990 |
| Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies |
Completed |
Acute Myeloid Leukemia|Infantile Leukemia (Both AML and ALL)|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasms|Biphenotypic Leukemia |
NCT00908167 |
| Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma |
Completed |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm |
NCT00474929 |
| Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients |
Unknown status |
Adrenocortical Carcinoma |
NCT00786110 |
| Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation |
Completed |
Metastatic Colorectal Cancer |
NCT00989469 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors |
Active, not recruiting |
Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm |
NCT02143401 |
| A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT00492752 |
| A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer |
Terminated |
Metastatic Breast Cancer |
NCT00632541 |
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer |
Terminated |
Kidney Cancer |
NCT00589550 |
| Sorafenib and RAD001 Renal Cell Carcinoma |
Completed |
Renal Cell Carcinoma |
NCT00384969 |
| BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00098254 |
| Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer |
Completed |
Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma |
NCT00093626 |
| Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Recurrent Adult Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma |
NCT01900002 |
| Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia |
Terminated |
Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia |
NCT00303966 |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations |
Active, not recruiting |
Advanced Malignant Neoplasm|BRAF Gene Mutation|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm |
NCT01531361 |
| Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis |
Completed |
Liver Cancer |
NCT01075555 |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) |
Completed |
Carcinoma, Hepatocellular |
NCT00692770 |
| Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer |
NCT00600015 |
| Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT01131689 |
| Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma |
Recruiting |
Glioblastoma|Recurrent Adult Brain Neoplasm|Malignant Glioma|WHO Grade III Glioma |
NCT01817751 |
| Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients |
Completed |
Neoplasms |
NCT00259129 |
| The Effect of Telephone Counseling on the Compliance and Satisfaction for Advanced HCC Patients Receiving Sorafenib |
Unknown status |
Hepatocellular Carcinoma |
NCT02564666 |
| Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients |
Unknown status |
Breast Cancer |
NCT00954135 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer |
Completed |
Chromophobe Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IV Renal Cell Cancer |
NCT00126503 |
| Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate |
Active, not recruiting |
Gastrointestinal Stromal Tumor |
NCT00265798 |
| Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer |
Completed |
Hepatocellular Carcinoma|Liver Cancer |
NCT01264705 |
| Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00390611 |
| Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Completed |
Refractory Multiple Myeloma |
NCT00253578 |
| S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas |
Completed |
Sarcoma |
NCT00217620 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function |
Completed |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia |
NCT00118170 |
| Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT02981498 |
| BAY43-9006 - Phase II in Advanced Breast Cancer |
Completed |
Breast Neoplasms|Breast Cancer |
NCT00101400 |
| Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer |
Terminated |
Carcinoma, Hepatocellular |
NCT00699374 |
| Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer |
Completed |
Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer |
NCT00182689 |
| Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas |
Completed |
Advanced Solid Tumors|Lymphomas |
NCT00788099 |
| A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC |
Completed |
Advanced Adult Hepatocellular Carcinoma |
NCT01829035 |
| Sorafenib + mFOLFOX for Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Cancer |
NCT01775501 |
| Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer |
Completed |
Primary Disease|Prostate Cancer |
NCT00405210 |
| Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT03812770 |
| Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma |
NCT01348503 |
| Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients |
Completed |
Multiple Myeloma |
NCT00536575 |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium |
Terminated |
Adenocarcinoma of the Bladder|Distal Urethral Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Proximal Urethral Cancer|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Squamous Cell Carcinoma of the Bladder|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Urethral Cancer Associated With Invasive Bladder Cancer |
NCT00112905 |
| An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02576509 |
| Metastatic Advanced Pancreas Sorafenib |
Unknown status |
Locally Advanced Pancreatic Cancer |
NCT00758381 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma |
Completed |
Melanoma|Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma |
NCT00349206 |
| Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery |
Completed |
Liver Cancer |
NCT00949182 |
| Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma |
Completed |
Advanced Hepatocarcinoma |
NCT01418729 |
| Randomized Phase II Trial of Chemoembolization and Sorafenib |
Withdrawn |
Hepatocellular Carcinoma |
NCT02908165 |
| Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer |
Completed |
Advanced Malignant Neoplasm |
NCT00244972 |
| Sorafenib and Bortezomib in Treating Patients With Advanced Cancer |
Completed |
Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Stage III Multiple Myeloma|Stage IV Chronic Lymphocytic Leukemia|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00303797 |
| Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00828074 |
| Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
Completed |
Nasopharyngeal Neoplasms |
NCT00747799 |
| A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma |
Unknown status |
Uveal Melanoma |
NCT01377025 |
| Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma |
Unknown status |
Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma |
NCT00752063 |
| Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma |
NCT00828594 |
| A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT00105443 |
| Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma |
Completed |
Lung Cancer |
NCT00456716 |
| HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial |
Recruiting |
Hepatocellular Carcinoma |
NCT04135690 |
| Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) |
Unknown status |
HCC |
NCT01265576 |
| A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). |
Completed |
Carcinoma, Hepatocellular |
NCT00855218 |
| Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) |
Withdrawn |
Locally Metastatic Malignant Neoplasm |
NCT01616186 |
| External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer |
Completed |
Colorectal Cancer |
NCT00869570 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia |
Terminated |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13 |
NCT01159301 |
| ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer |
Recruiting |
Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Metastatic Liver Cancer |
NCT03965546 |
| A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] |
Recruiting |
Carcinoma, Hepatocellular |
NCT03434379 |
| Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT |
Enrolling by invitation |
Carcinoma, Hepatocellular|Portal Vein Tumor Thrombus |
NCT04127396 |
| Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
Pulmonary Arterial Hypertension |
NCT00452218 |
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT02035527 |
| A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT00044512 |
| Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma |
Terminated |
Advanced Adult Hepatocellular Carcinoma |
NCT01405573 |
| Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 |
Withdrawn |
Hepatocellular Carcinoma |
NCT02129322 |
| Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer |
Active, not recruiting |
Adult Primary Hepatocellular Carcinoma|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer |
NCT01624285 |
| Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers |
Completed |
Renal Cancer|Tumors |
NCT00398814 |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer |
Active, not recruiting |
Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Advanced Adult Hepatocellular Carcinoma|BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma |
NCT01666756 |
| Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00619996 |
| Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00826540 |
| Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. |
Completed |
Carcinoma, Hepatocellular |
NCT01204177 |
| Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer |
Completed |
Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma |
NCT01008566 |
| Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) |
Withdrawn |
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) |
NCT00627835 |
| Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients |
Withdrawn |
Hepatocyte Receptor|Hepatocellular Carcinoma |
NCT03113604 |
| A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT00712855 |
| Sorafenib for Residue Disease After Resection With Curative Intent |
Completed |
Carcinoma, Hepatocellular |
NCT01751763 |
| A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01897038 |
| Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma |
Terminated |
Carcinoma, Hepatocellular |
NCT01171482 |
| Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer |
Completed |
Thyroid Neoplasms |
NCT00984282 |
| Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma |
Completed |
Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma |
NCT00278382 |
| Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma |
Withdrawn |
Glioblastoma|Gliosarcoma |
NCT02599090 |
| Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma |
Recruiting |
Liver Cancer|Hepatic Carcinoma |
NCT03164382 |
| HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT03775395 |
| Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases |
Completed |
Tumors Metastatic to Brain |
NCT01276210 |
| Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) |
Unknown status |
Hepatocellular Carcinoma |
NCT00823290 |
| Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment |
Completed |
Metastatic Breast Cancer |
NCT01320111 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma |
Completed |
Adult Angiosarcoma|Adult Epithelioid Sarcoma|Adult Leiomyosarcoma|Adult Malignant Fibrous Histiocytoma|Adult Neurofibrosarcoma|Adult Synovial Sarcoma|Ovarian Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Uterine Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage III Uterine Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Stage IV Uterine Sarcoma|Uterine Carcinosarcoma|Uterine Leiomyosarcoma |
NCT00245102 |
| Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00473486 |
| Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT02400788 |
| Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery |
Completed |
Stage III Melanoma|Stage IV Melanoma |
NCT00119249 |
| Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. |
Completed |
Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant Mesothelioma |
NCT00107432 |
| Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
Active, not recruiting |
Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Squamous Cell Carcinoma of the Hypopharynx|Metastatic Squamous Cell Carcinoma of the Larynx|Metastatic Squamous Cell Carcinoma of the Oral Cavity|Metastatic Squamous Cell Carcinoma of the Oropharynx|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma |
NCT00494182 |
| Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study) |
Terminated |
Renal Cancer Cell |
NCT03456401 |
| Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT01687673 |
| A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma (HCC) |
NCT01761266 |
| Sorafenib With TACE to Treat Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT00478374 |
| Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
Unknown status |
Hepatocellular Cancer |
NCT01078311 |
| Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract |
Completed |
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder |
NCT00112671 |
| Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia |
Completed |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15 |
NCT00131989 |
| Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer |
Terminated |
Ovarian Cancer |
NCT00526799 |
| Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) |
Completed |
Prostate Cancer |
NCT00424385 |
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) |
Unknown status |
Hepatocellular Carcinoma |
NCT01170104 |
| A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma |
Completed |
Melanoma |
NCT00492297 |
| Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib. |
Recruiting |
Hepatocellular Carcinoma|Perfusion Scanner |
NCT03140332 |
| Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer |
Completed |
Recurrent Breast Cancer|Stage IV Breast Cancer |
NCT00217399 |
| Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT00901901 |
| BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Lung Cancer |
NCT00533585 |
| BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma |
Terminated |
Kaposi's Sarcoma|HHV-8|KSHV |
NCT00287495 |
| Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00098540 |
| Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme |
Completed |
Brain and Central Nervous System Tumors |
NCT00621686 |
| Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery |
Terminated |
Liver Cancer |
NCT00873002 |
| Phase 1 Study With Sorafenib and Sirolimus |
Completed |
Advanced Solid Tumor|Refractory to Standard Therapies |
NCT00509613 |
| DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma |
Not yet recruiting |
Hepatocellular Carcinoma |
NCT04229355 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT00096512 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia |
Completed |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22) |
NCT00217646 |
| Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer |
Terminated |
Colorectal Neoplasms |
NCT00889343 |
| Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety |
Completed |
Carcinoma, Hepatocellular |
NCT01908322 |
| Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer |
Completed |
Breast Cancer |
NCT01234337 |
| Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT00619541 |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) |
Completed |
Metastatic Disease|Renal Cell Carcinoma |
NCT00609401 |
| Sorafenib in Treating Patients With Advanced Solid Tumors |
Terminated |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00436579 |
| Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer |
Completed |
Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors |
NCT01502410 |
| Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma |
Completed |
Pancreatic Cancer |
NCT00789763 |
| Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy |
Completed |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer |
NCT00919061 |
| Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer |
Active, not recruiting |
Advanced Adult Hepatocellular Carcinoma|Recurrent Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma |
NCT01015833 |
| North Carolina |
Brevard |
United States|Novant Health Presbyterian Medical Center |
Asheville |
| Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006 |
Completed |
Kidney Diseases |
NCT00119639 |
| BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00326495 |
| Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00126620 |
| BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) |
Completed |
Cancer|Carcinoma, Non-Small Cell Lung |
NCT00101413 |
| Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00255658 |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma |
Completed |
Malignant Melanoma |
NCT00498836 |
| Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) |
Completed |
Carcinoma |
NCT00941863 |
| Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients |
Completed |
Hepatocellular Carcinoma |
NCT01481805 |
| Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer |
Completed |
Carcinoma, Renal Cell |
NCT00448149 |
| Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Completed |
Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT00095966 |
| Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT00389285 |
| Sorafenib. ICORG 06-41, V4 |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT01158287 |
| HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC |
Withdrawn |
Hepatocellular Carcinoma |
NCT03780634 |
| Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies |
Completed |
Acute Myeloid Leukemia |
NCT02270788 |
| A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC |
Recruiting |
Locally Advanced or Metastatic and Unresectable HCC |
NCT03764293 |
| Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects |
Completed |
Metastatic Colorectal Cancer |
NCT00865709 |
| Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer |
Completed |
Recurrent Uterine Sarcoma|Stage III Uterine Sarcoma|Stage IV Uterine Sarcoma|Uterine Carcinosarcoma |
NCT00238121 |
| Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme |
Completed |
Glioblastoma Multiforme |
NCT00544817 |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma |
Terminated |
Hepatocellular Carcinoma|Hepatoma|Liver Cell Carcinoma |
NCT02460991 |
| Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment |
Completed |
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment) |
NCT01262482 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
Completed |
Gastrinoma|Glucagonoma|Insulinoma|Metastatic Gastrointestinal Carcinoid Tumor|Neuroendocrine Tumor|Pancreatic Polypeptide Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma|WDHA Syndrome |
NCT00131911 |
| Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain |
Completed |
Kidney Cancer|Metastatic Cancer |
NCT00301847 |
| 18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib |
Recruiting |
HCC |
NCT02977754 |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) |
Terminated |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent|Carcinoma, Hepatocellular|Liver Diseases|Neoplasms by Histologic Type|Digestive System Neoplasms|Carcinoma|Liver Neoplasms|Neoplasms|Neoplasms by Site|Digestive System Diseases|Adenocarcinoma|Neoplasms, Glandular and Epithelial |
NCT01009593 |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer |
Completed |
Adenocarcinoma of the Gastroesophageal Junction|Metastatic Gastric Cancer|Advanced Unresectable Gastric Cancer |
NCT00253370 |
| A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT02240433 |
| Sorafenib in Elderly mRCC |
Completed |
Carcinoma, Renal Cell |
NCT01728948 |
| Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer |
Completed |
Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer |
NCT01383343 |
| Sorafenib in Urothelium Cancer of Bladder |
Terminated |
Bladder Cancer |
NCT01215266 |
| Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients |
Withdrawn |
Hepatic Neoplasm Malignant |
NCT01245582 |
| Long-term Extension From RCC Phase II (11515) |
Completed |
Carcinoma, Renal Cell |
NCT00586495 |
| Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery |
Completed |
Pancreatic Cancer |
NCT00837876 |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery |
Completed |
Recurrent Melanoma|Stage IV Melanoma |
NCT00281957 |
| Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma |
Completed |
Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm |
NCT00329719 |
| Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT00464919 |
| Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers |
Completed |
Healthy, Male |
NCT03674060 |
| Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma |
Active, not recruiting |
Pleomorphic Rhabdomyosarcoma|Stage IIB Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7|Stage IV Adult Soft Tissue Sarcoma AJCC v7 |
NCT02050919 |
| Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) |
Completed |
Carcinoma, Hepatocellular |
NCT00919009 |
| Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib |
Completed |
Carcinoma, Hepatocellular |
NCT00812175 |
| A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00558636 |
| Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination |
Completed |
Uveal Melanoma |
NCT02517736 |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00134069 |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin |
Terminated |
Renal Cell Carcinoma|Hepatocellular Carcinoma|Colorectal Carcinoma |
NCT01466504 |
| Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer |
Completed |
Ovarian Neoplasms |
NCT00791778 |
| Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
Completed |
Leukemia|Myelodysplastic Syndromes |
NCT00516828 |
| Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00573690 |
| Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer |
Completed |
Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer |
NCT00126594 |
| Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer |
Completed |
Stage IV Pancreatic Cancer |
NCT00114244 |
| Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant |
Recruiting |
Allogeneic Hematopoietic Stem Cell Transplant Recipient|Donor|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia |
NCT03247088 |
| A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment |
Completed |
Hepatocellular Carcinoma |
NCT01232296 |
| Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer |
Completed |
Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer |
NCT00096395 |
| Sorafenib Gastric Cancer Asian Phase I Study |
Completed |
Gastric Cancer |
NCT00663741 |
| Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye |
Completed |
Ciliary Body and Choroid Melanoma, Medium/Large Size|Extraocular Extension Melanoma|Iris Melanoma|Metastatic Intraocular Melanoma|Recurrent Intraocular Melanoma |
NCT00329641 |
| Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia |
Active, not recruiting |
Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16 |
NCT01253070 |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission |
Terminated |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00522301 |
| Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein |
Terminated |
Hepatocellular Carcinoma |
NCT01887717 |
| Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT00111020 |
| Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT01157013 |
| A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective |
Completed |
Metastatic Hepatocellular Carcinoma|Advanced Liver Cancer |
NCT01754987 |
| HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT02856126 |
| HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT03812783 |
| Study in Asia of the Combination of TACE With Sorafenib in HCC Patients |
Unknown status |
Hepatocellular Carcinoma |
NCT00990860 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer |
Terminated |
Clear Cell Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer |
NCT00098618 |
| Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00547443 |
| Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01004003 |
| Extension Program for Bay 43-9006 |
Completed |
Neoplasm|Metastasis |
NCT00657254 |
| 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00121264 |
| Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) |
Completed |
Hepatocellular Carcinoma |
NCT00976170 |
| Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery |
Unknown status |
Liver Cancer |
NCT01182272 |
| A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer |
Completed |
Advanced Hepatocellular Carcinoma|Inoperable Hepatocellular Carcinoma |
NCT00872014 |
| Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride |
Completed |
Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00981162 |
| Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00726986 |
| Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma |
Completed |
Recurrent Melanoma|Stage III Skin Melanoma|Stage IV Skin Melanoma |
NCT00387751 |
| Sorafenib in Previously Treated Malignant Mesothelioma |
Unknown status |
Mesothelioma |
NCT00794859 |
| CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma |
Completed |
Pancreatic Neoplasms|Bile Duct Neoplasms |
NCT00634751 |
| Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer |
Completed |
Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 |
NCT00121251 |
| Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer |
Completed |
Liver Cancer |
NCT00867321 |
| Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer |
Completed |
Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer |
NCT00101114 |
| S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma |
Completed |
Adenocarcinoma of the Extrahepatic Bile Duct|Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Squamous Cell Carcinoma of the Gallbladder|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer |
NCT00238212 |
| Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) |
Completed |
Adenocarcinoma |
NCT00661830 |
| Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer |
Completed |
Liver Cancer |
NCT00881751 |
| BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT00117637 |
| Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) |
Completed |
Carcinoma, Hepatocellular |
NCT00494299 |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
Active, not recruiting |
Advanced Cancer |
NCT01187199 |
| Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery |
Unknown status |
Sarcoma |
NCT00874874 |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies |
Completed |
Advanced Solid Tumor |
NCT00449280 |
| Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor |
Recruiting |
Solid Tumor |
NCT03406364 |
| Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer |
Withdrawn |
Carcinoma, Renal Cell |
NCT01353794 |
| Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib |
Recruiting |
Hepatocellular Carcinoma |
NCT02786342 |
| Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer |
Completed |
Prostate Cancer |
NCT00093457 |
| Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer |
Recruiting |
Pancreatic Adenocarcinoma|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Recurrent Pancreatic Carcinoma |
NCT02349867 |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. |
Recruiting |
Hepatocellular Carcinoma |
NCT03794440 |
| Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma |
Completed |
Sarcoma |
NCT00822848 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery |
Completed |
Clear Cell Renal Cell Carcinoma|Stage I Renal Cell Cancer AJCC v6 and v7|Stage II Renal Cell Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7 |
NCT00326898 |
| United States|Etzell |
Fergus Falls |
United States|Lake Region Healthcare Corporation-Cancer Care |
Minnesota |
| United States|HSHS Sacred Heart Hospital |
Wisconsin |
Eau Claire |
Wisconsin |
| Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma |
Completed |
Renal Cell Carcinoma |
NCT00876382 |
| A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00449033 |
| Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00696696 |
| Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery |
Completed |
Liver Cancer |
NCT00875615 |
| Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00454194 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy |
Recruiting |
Hepatocellular Carcinoma |
NCT03755791 |
| Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer |
Completed |
Carcinoma, Renal Cell |
NCT00079612 |
| MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma |
Completed |
Metastatic Renal Cell Carcinoma |
NCT00606866 |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
Completed |
Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor |
NCT00335764 |
| Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib |
Terminated |
Carcinoma, Renal Cell |
NCT00352859 |
| Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Terminated |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00687674 |
| A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00607438 |
| Sorafenib in Treating Patients With Metastatic Breast Cancer |
Completed |
Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer |
NCT00096434 |
| Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT01508364 |
| Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma |
Unknown status |
Melanoma (Skin) |
NCT00602576 |
| Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) |
Terminated |
Metastatic Prostate Cancer |
NCT00452387 |
| SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT03578874 |
| Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer |
Completed |
Breast Cancer |
NCT00544167 |
| Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Carcinoma, Hepatocellular |
NCT00490685 |
| Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
Completed |
Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor |
NCT00445588 |
| Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer |
Completed |
Liver Cancer |
NCT00941967 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer |
Terminated |
Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer |
NCT00095693 |
| Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma |
NCT01004978 |
| Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Hepatectomy|Hepatocellular Carcinoma|Sorafenib |
NCT01409499 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT00939627 |
| Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC |
Completed |
Carcinoma, Renal Cell |
NCT00496301 |
| The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
Unknown status |
Hepatocellular Carcinoma (HCC) |
NCT03236649 |
| Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma |
Completed |
HCC |
NCT02645981 |
| Residual Plasma Concentration of Sorafenib and Adverse Events in CHC |
Unknown status |
Advanced or Metastatic Hepatocellular Carcinoma |
NCT03340636 |
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction |
Completed |
Hepatocellular Carcinoma |
NCT03212625 |
| Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib |
Completed |
Renal Cell Carcinoma |
NCT00474786 |
| Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer |
Completed |
Hepatocellular Carcinoma |
NCT02101593 |
| Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) |
Completed |
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Osteosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Osteosarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma |
NCT00330421 |
| HCC Patient Preferences in Japan |
Completed |
Hepatocellular Cancer |
NCT02616692 |
| BAY43-9006 Phase II Study for Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT00661375 |
| Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer |
Terminated |
Non-Small Cell Lung Cancer |
NCT00417248 |
| Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib |
Completed |
Metastatic Renal Cell Cancer|GIST |
NCT01246843 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
Recruiting |
Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Myeloproliferative Neoplasm |
NCT02728050 |
| An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma |
Completed |
Carcinoma, Renal Cell |
NCT00492986 |
| Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer |
Completed |
Kidney Cancer |
NCT00492258 |
| Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy |
Completed |
Prostate Cancer |
NCT00589420 |
| A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma |
Completed |
Malignant Melanoma |
NCT00483301 |
| Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma |
Completed |
Melanoma |
NCT00623402 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
Completed |
Mucosal Melanoma|Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma |
NCT00110019 |
| Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer |
Completed |
Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v7 |
NCT00378703 |
| Pennsylvania |
Scranton |
United States|Geisinger Medical Group |
Scranton |
| Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg |
Completed |
Melanoma (Skin) |
NCT00565968 |
| Sequential Study to Treat Renal Cell Carcinoma |
Completed |
Renal Cell Carcinoma |
NCT00732914 |
| INSIGHT - Post Marketing Surveillance |
Completed |
Carcinoma, Hepatocellular |
NCT00792350 |
| A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01308723 |
| Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Completed |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma |
NCT00096200 |
| Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer |
Completed |
Adenocarcinoma of the Prostate|Stage II Prostate Cancer|Stage III Prostate Cancer |
NCT00466752 |
| Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Unknown status |
Pancreatic Cancer |
NCT00541021 |
| Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT00499525 |
| Sorafenib to Treat FLT3-ITD AML |
Recruiting |
Acute Myeloid Leukemia|FLT3-ITD Mutation |
NCT02156297 |
| First Line Hepato Cellular Carcinoma (HCC) |
Completed |
Hepato Cellular Carcinoma (HCC) |
NCT00858871 |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) |
Completed |
Advanced Cancers |
NCT01183663 |
| Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer |
Completed |
Carcinoma, Renal Cell |
NCT00073307 |
| Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment |
Terminated |
Carcinoma, Hepatocellular |
NCT01108705 |
| Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar |
Completed |
Carcinoma, Renal Cell|Carcinoma, Renal Cell (Advanced) |
NCT00895674 |
| Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment |
Completed |
Liver Cancer |
NCT00825955 |
| A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib |
Completed |
Hepatocellular Carcinoma|Liver Cancer|HCC |
NCT01387555 |
| Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec |
Completed |
Chronic Myelogenous Leukemia |
NCT00661180 |
| Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST |
Completed |
Renal Cell Cancer|Colorectal Cancer|GIST |
NCT00979329 |
| A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-NaĂŻve Hormone Refractory Prostate Cancer |
Completed |
Adenocarcinoma of the Prostate |
NCT00430235 |
| Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer |
Completed |
Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer |
NCT01042041 |
| Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma |
Completed |
Cancer|Melanoma |
NCT00110994 |
| A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® |
Completed |
Carcinoma, Renal Cell|Carcinoma, Renal Cell (Advanced) |
NCT00771147 |
| A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver |
Completed |
Hepatocellular Carcinoma |
NCT00906373 |
| HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC |
Unknown status |
Hepatocellular Carcinoma |
NCT03468231 |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors |
Completed |
Neoplasms |
NCT00095459 |
| Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib |
Recruiting |
Carcinoma, Hepatocellular |
NCT02847468 |
| Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma |
Unknown status |
Melanoma (Skin) |
NCT00538005 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer |
Active, not recruiting |
Advanced Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 |
NCT01664182 |
| Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) |
Terminated |
Renal Cell Carcinoma |
NCT00672178 |
| Adjuvant Therapies for Patients With HCC and MVI |
Recruiting |
Hepatocellular Carcinoma |
NCT02436902 |
| Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate |
Completed |
Lung Cancer |
NCT01124669 |
| AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib |
Completed |
Advanced Renal Cell Carcinoma |
NCT00467025 |
| Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00573755 |
| Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib |
Recruiting |
Hepatocarcinoma |
NCT03956940 |
| 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy |
Completed |
Breast Cancer |
NCT00493636 |
| A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma |
Completed |
Melanoma |
NCT00111007 |
| Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung|Lung Cancer |
NCT01069328 |
| Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma |
Unknown status |
Melanoma (Skin) |
NCT00492505 |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. |
Completed |
Advanced Solid Tumors |
NCT00861419 |
| Regulatory Post Marketing Surveillance Study on Nexavar® |
Completed |
Carcinoma, Hepatocellular|Carcinoma, Renal Cell |
NCT01012011 |
| Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery |
Completed |
Liver Cancer |
NCT01011010 |
| Sorafenib-induced Hand- Foot Skin Reaction Treatment |
Terminated |
Hand-foot Skin Reaction|Rash |
NCT00667589 |
| Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma |
Completed |
Advanced Adult Hepatocellular Carcinoma |
NCT01777594 |
| A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib |
Recruiting |
Carcinoma, Hepatocellular |
NCT03008512 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
Active, not recruiting |
Acute Myeloid Leukemia|Leukemia Cutis|Myeloid Neoplasm|Myeloid Sarcoma |
NCT01371981 |
| Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy |
Terminated |
Malignant Neoplasm |
NCT00532064 |
| BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas |
Completed |
Sarcoma, Soft Tissue |
NCT00406601 |
| Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis |
Completed |
Hepatocellular Carcinoma|CHILD B |
NCT01357486 |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas |
Completed |
Neurofibromatosis Type I|Plexiform Neurofibroma |
NCT00727233 |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia |
Recruiting |
Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia |
NCT03132454 |
| Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma |
Unknown status |
Melanoma (Skin) |
NCT00811759 |
| Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy |
Unknown status |
Lung Cancer |
NCT00801385 |
| A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT00108953 |
| A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib |
Completed |
Hepatocellular Carcinoma |
NCT01140347 |
| Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment |
Active, not recruiting |
Carcinoma, Hepatocellular |
NCT03389126 |
| Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma |
Recruiting |
Overall Survival|Tumor Responses |
NCT03275376 |
| Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT01908426 |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma |
Active, not recruiting |
Carcinoma, Hepatocellular |
NCT01988493 |
| A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma |
Withdrawn |
Carcinoma, Hepatocellular |
NCT02939807 |
| GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start |
Withdrawn |
Carcinoma, Hepatocellular |
NCT01191385 |
| Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01774344 |
| Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma |
Terminated |
Melanoma |
NCT00673361 |
| Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder |
Unknown status |
Bladder Cancer |
NCT01222676 |
| Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy |
Terminated |
Hepatocellular Carcinoma |
NCT00687596 |
| Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery |
Unknown status |
Liver Cancer |
NCT01324076 |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma |
NCT04039607 |
| A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naĂŻve Advanced Liver Cancer |
Completed |
Hepatocellular Carinoma |
NCT01636284 |
| Irradiation Stent Placement Plus TACE for HCC and PVTT |
Recruiting |
Hepatocellular Carcinoma|Portal Vein Tumor Thrombosis |
NCT03730675 |
| A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02178358 |
| Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial |
Completed |
Acute Myeloid Leukemia |
NCT02867891 |
| Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer |
Available |
Gastric Cancer. |
NCT02209441 |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib |
Completed |
Hepatocellular Carcinoma|Hepatocellular Cancer|Carcinoma, Hepatocellular |
NCT01375569 |
| Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer |
Recruiting |
Advanced Liver Cancer |
NCT04163237 |
| MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. |
Completed |
Unresectable or Metastatic Hepatocellular Carcinoma (HCC) |
NCT01498952 |
| Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) |
Completed |
Carcinoma, Renal Cell |
NCT01381601 |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors |
Completed |
Advanced Malignancy|Advanced Solid Tumors|Cancer|Solid Tumors|Tumors |
NCT00974896 |
| Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC |
Completed |
Advanced Hepatocellular Carcinoma |
NCT01897610 |
| Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets |
Completed |
Metastatic Renal Cell Carcinoma |
NCT02406521 |
| A Study to Evaluate SHR-1210 in Combination With FOLFOX4 Regimen as First-Line Therapy in Subjects With Advanced HCC |
Recruiting |
Advanced Hepatocellular Carcinoma |
NCT03605706 |
| Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma |
Recruiting |
HepatoCellular Carcinoma |
NCT04152356 |
| The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial |
Terminated |
Hepatocellular Carcinoma |
NCT02220088 |
| Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer |
Completed |
Head and Neck Neoplasms |
NCT00199160 |
| Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer |
Completed |
Kidney Neoplasms |
NCT00678392 |
| 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain |
Active, not recruiting |
Metastatic Breast Cancer to the Brain |
NCT01621906 |
| A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients |
Completed |
Carcinoma, Hepatocellular |
NCT00987935 |
| Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor |
Completed |
Renal Cell Carcinoma|GIST |
NCT00979381 |
| Bevacizumab in Multiple Phase I Combinations |
Active, not recruiting |
Advanced Cancer |
NCT00543504 |
| An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT01658878 |
| Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) |
Completed |
Carcinoma, Renal Cell |
NCT01381614 |
| DKN-01 Inhibition in Advanced Liver Cancer |
Recruiting |
Hepatocellular Carcinoma |
NCT03645980 |
| SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) |
Completed |
Hepatocellular Carcinoma |
NCT01752933 |
| TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer |
Recruiting |
Carcinoma, Hepatocellular |
NCT02794337 |
| c-Met Second-Line Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT02115373 |
| Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer |
Active, not recruiting |
Kidney Neoplasms |
NCT00920816 |
| Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma |
Completed |
Carcinoma, Hepatocellular |
NCT01655693 |
| Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia |
Completed |
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies |
NCT01576185 |
| An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors |
Active, not recruiting |
Thyroid Neoplasms |
NCT02303444 |
| Hepatic Impairment Study |
Completed |
Liver Disease |
NCT00829231 |
| Research Study for Patients With Metastatic Renal Cell Carcinoma |
Terminated |
Carcinoma, Renal Cell |
NCT00110344 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer |
Active, not recruiting |
Thyroid Cancer|Thyroid Cancer, Medullary|Differentiated Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma |
NCT03630120 |
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma |
Terminated |
Liver Carcinoma |
NCT00791544 |
| Fingerprint Characterization of Advanced HCC |
Completed |
Carcinoma, Hepatocellular |
NCT02372162 |
| Circulating Tumor Cells and Tumor DNA in HCC and NET |
Recruiting |
Carcinoma, Hepatocellular|Neuroendocrine Tumors |
NCT02973204 |
| A Study of LY2157299 in Participants With Hepatocellular Carcinoma |
Active, not recruiting |
Carcinoma, Hepatocellular |
NCT01246986 |
| Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors |
Unknown status |
Recurrent Childhood Brain Tumor |
NCT02015728 |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE |
Completed |
Kidney Cancer |
NCT00900536 |
| Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) |
Recruiting |
Hepatocellular Carcinoma |
NCT04170556 |
| Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy |
Terminated |
Carcinoma, Renal Cell |
NCT01195649 |
| Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate |
Completed |
Melanoma (Skin) |
NCT01209299 |
| Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) |
Not yet recruiting |
Hepatocellular Carcinoma |
NCT04316182 |
| Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib |
Recruiting |
Hepatocellular Carcinoma |
NCT03163992 |
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance |
Active, not recruiting |
Solid Tumors|Advanced Cancer |
NCT01197170 |
| The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma |
Withdrawn |
Hepatocellular Carcinoma|Lung Metastasis |
NCT01953406 |
| A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) |
Completed |
Liver Cancer |
NCT02029157 |
| Hepatic Monitoring for Pazopanib |
Completed |
Carcinoma, Renal Cell |
NCT01449825 |
| Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer |
Terminated |
Hepatocellular Carcinoma |
NCT02089763 |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine |
Withdrawn |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent |
NCT03563170 |
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate |
Terminated |
Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer |
NCT01582009 |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. |
Completed |
Carcinoma |
NCT01035229 |
| Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study |
Unknown status |
Advanced Solid Tumors|Inoperable|Metastasis |
NCT01190241 |
| Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) |
Recruiting |
Advanced/ Metastatic Hepatocellular Carcinoma |
NCT03499626 |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma |
Withdrawn |
Advanced Hepatocellular Carcinoma |
NCT01964235 |
| Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting |
Recruiting |
Metastatic Renal Cell Carcinoma (mRCC) |
NCT02184416 |
| BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer |
Active, not recruiting |
Lung Cancer |
NCT01248247 |
| Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML |
Enrolling by invitation |
FLT3-ITD Mutation|Acute Myeloid Leukemia|Brutons Tyrosine Kinase |
NCT03642236 |
| Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT03298451 |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy |
Recruiting |
Neuroblastoma |
NCT02559778 |
| Sequential Therapy in Metastatic Renal Cell Carinoma |
Completed |
Metastatic Renal Cell Carcinoma |
NCT01731158 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia |
Recruiting |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia |
NCT01620216 |
| Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer |
Active, not recruiting |
Unresectable Hepatocellular Carcinoma |
NCT01556490 |
| Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor |
Completed |
Solid Tumors |
NCT00495872 |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. |
Withdrawn |
Carcinoma, Renal Cell|Glioblastoma|Carcinoma, Hepatocellular |
NCT01441388 |
| Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC |
Recruiting |
Hepatocellular Carcinoma |
NCT03899428 |
| RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib |
Completed |
Metastatic Renal Cell Carcinoma |
NCT00410124 |
| Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery |
Recruiting |
Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Fibrolamellar Carcinoma|Hepatoblastoma|Hepatocellular Malignant Neoplasm, Not Otherwise Specified |
NCT03533582 |
| A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study |
Unknown status |
Gastrointestinal Cancers |
NCT02013089 |
| ABT-888 and Temozolomide for Liver Cancer |
Terminated |
Hepatocellular Carcinoma |
NCT01205828 |
| Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy |
Active, not recruiting |
Liver Cancer |
NCT01180959 |
| A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein |
Recruiting |
Hepatocellular Carcinoma |
NCT02435433 |
| A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC |
Terminated |
Advanced Hepatocellular Carcinoma (HCC) |
NCT01101906 |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC |
Completed |
Hepatocellular Carcinoma (HCC) |
NCT03516071 |
| Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors |
Active, not recruiting |
Advanced Malignant Solid Neoplasm|Hepatocellular Carcinoma |
NCT01628640 |
| Study of Pembrolizumab and Radiotherapy in Liver Cancer |
Recruiting |
Hepatocellular Carcinoma |
NCT03316872 |
| Personalized Targeted Inhibitors Treatment in Renal Cell Cancer |
Terminated |
Carcinoma, Renal Cell |
NCT02560012 |
| Cardiovascular and Torsades de Pointes Monitoring for Pazopanib |
Completed |
Carcinoma, Renal Cell |
NCT01446224 |
| A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies |
Completed |
Cancer |
NCT01224730 |
| A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer |
Terminated |
Carcinoma, Hepatocellular |
NCT01911273 |
| Epigenetic Reprogramming in Relapse AML |
Terminated |
Leukemia, Acute Myeloid |
NCT02412475 |
| CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) |
Completed |
Metastatic Renal Cell Carcinoma |
NCT02187302 |
| A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia |
Recruiting |
Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia |
NCT03878524 |
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours |
Unknown status |
Hepatocellular Carcinoma|Pancreatic Cancer |
NCT02423239 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia |
Recruiting |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia |
NCT02779283 |
| Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors |
Active, not recruiting |
Desmoplastic Small Round Cell Tumor|Ewing Sarcoma of Bone or Soft Tissue|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
NCT01946529 |
| Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients |
Terminated |
Renal Cell Cancer |
NCT02071719 |
| Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy |
Recruiting |
Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML |
NCT02638428 |
| Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment |
Recruiting |
Malignant Solid Neoplasms |
NCT02029001 |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors |
Unknown status |
Differentiated Thyroid Cancer |
NCT01700699 |
| Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy |
Recruiting |
Rhabdomyosarcoma |
NCT01871766 |
| Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) |
Recruiting |
Hepatocellular Carcinoma |
NCT04167293 |
| Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) |
Recruiting |
Hepatocellular Carcinoma |
NCT03963206 |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma |
Terminated |
Renal Cell Carcinoma |
NCT01649180 |
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 |
Completed |
Neurofibromas|Neurofibromatosis Type 1 |
NCT00314119 |
| Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer |
Recruiting |
Rectal Cancer |
NCT02910843 |
| Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial |
Completed |
Liver Cancer |
NCT00717756 |
| Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma |
Recruiting |
Localized Non-Resectable Adult Hepatocellular Carcinoma |
NCT01910909 |
| Caphosol in Oral Mucositis Due to Targeted Therapy |
Completed |
Oral Complaints|Renal Cell Carcinoma|Hepatocellular Carcinoma|Gastrointestinal Stromal Tumors |
NCT01265810 |
| A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer |
Completed |
Renal Cell Carcinoma |
NCT00448721 |
| SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes |
Recruiting |
Liposarcoma|Osteogenic Sarcoma|Ewing/Ewing-like Sarcoma|Rhabdomyosarcoma |
NCT02048371 |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) |
Terminated |
Renal Cell Carcinoma |
NCT02338570 |
| Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer |
Completed |
Kidney Neoplasms|Carcinoma, Renal Cell |
NCT00282048 |
| Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer |
Recruiting |
Cancer |
NCT02751827 |
| Temsirolimus as Second-line Therapy in HCC |
Unknown status |
Unresectable or Metastatic Hepatocellular Carcinoma |
NCT01567930 |
| Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01498458 |
| Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment |
Active, not recruiting |
Metastatic Renal Cell Carcinoma |
NCT02789137 |
| Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma |
Unknown status |
Quality of Life |
NCT01747642 |
| [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma |
NCT03648073 |
| Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT01949194 |
| A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor |
Completed |
Metastatic Renal Cell Carcinoma (mRCC) |
NCT01390519 |
| Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer |
Completed |
Renal Cell Carcinoma |
NCT00923130 |
| Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma |
Completed |
Liver Cancer |
NCT01545804 |
| Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer |
Unknown status |
Gastric Cancer|Hepatocellular Carcinoma |
NCT02942329 |
| Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant |
Recruiting |
Hepatocellular Carcinoma|Liver Transplantation |
NCT03966209 |
| Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) |
Active, not recruiting |
Hepatocellular Carcinoma |
NCT02702414 |
| Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma |
Recruiting |
Carcinoma, Hepatocellular |
NCT03732547 |
| Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck |
Unknown status |
Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck |
NCT02558387 |
| Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer |
Unknown status |
Kidney Cancer|Metastatic Cancer |
NCT01105364 |
| A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer |
Unknown status |
Reccurent/Metastatic Solid Tumor Disease |
NCT01771458 |
| Apatinib for Metastatic Esophageal Cancer. |
Unknown status |
Esophageal Cancer|Metastatic Esophageal Cancer|Apatinib |
NCT02544737 |
| A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus |
Unknown status |
Renal Cell Carcinoma|Nonclear Cell|Temsirolimus Resistance |
NCT01798446 |
| RAD001 for Patients With Radioiodine Refractory Thyroid Cancer |
Completed |
Thyroid Cancer |
NCT00936858 |
| First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer |
Recruiting |
Hepatocellular Carcinoma|Liver Cancer |
NCT02716012 |
| Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma |
Unknown status |
Hepatocellular Carcinoma |
NCT03066557 |
| An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy |
Withdrawn |
Carcinoma, Renal Cell |
NCT00538772 |
| Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer |
Recruiting |
Differentiated Thyroid Cancer |
NCT03048877 |
| Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial |
Recruiting |
Liver Neoplasm|Proton Therapy |
NCT02632864 |
| Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis |
Recruiting |
Liver Neoplasm|Portal Vein Tumor Thrombosis|Proton Therapy |
NCT02571946 |
| Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. |
Completed |
Renal Cell Carcinoma |
NCT01339962 |
| A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia |
Recruiting |
Acute Myeloid Leukemia|Myelodysplastic Syndromes |
NCT03164057 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer |
Recruiting |
Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma |
NCT03914300 |
| A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer |
Completed |
Advanced/ Metastatic Renal Cell Cancer |
NCT00715182 |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma |
Completed |
Renal Cell Carcinoma|Kidney Cancer |
NCT00782275 |
| Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma |
Completed |
Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity |
NCT03359018 |
| Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC) |
Unknown status |
Hepatocellular Carcinoma|Portal Vein Tumor Thrombosis |
NCT02290977 |
| A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection |
Recruiting |
Hepatocellular Carcinoma |
NCT03914352 |
| Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis |
Completed |
Carcinoma. Hepatocellular |
NCT01911000 |
| RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) |
Not yet recruiting |
Hepatocellular Carcinoma |
NCT04193696 |
| Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction |
Recruiting |
Hand Foot Skin Reaction |
NCT03229512 |
| MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma |
Not yet recruiting |
Carcinoma, Hepatocellular|Marker, Biological |
NCT02448056 |
| Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 |
Completed |
Salivary Gland Cancers |
NCT02857712 |
| Sarcopenia in Patients With Gastrointestinal Stromal Tumours |
Completed |
Gastrointestinal Stromal Tumours |
NCT02877368 |
| A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure |
Unknown status |
Hepatocellular Carcinoma |
NCT02772029 |
| Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment |
Completed |
Metastatic Renal Cell Carcinoma |
NCT02056587 |
| Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma |
NCT04162158 |
| Carbon Ion Radiotherapy for Hepatocellular Carcinoma |
Recruiting |
Hepatocellular Carcinoma |
NCT01167374 |
| pazopanib_NCRCC,Ph2 STUDY |
Completed |
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma |
NCT01538238 |
| Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection |
Recruiting |
Carcinoma, Hepatocellular |
NCT02738697 |
| TACE Combined With Iodine-125 Seeds Implantation for HCC |
Enrolling by invitation |
Hepatocellular Carcinoma|Portal Vein Occlusion|Tumor Thrombus |
NCT03322280 |
| Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation |
Recruiting |
Hepatocellular Carcinoma |
NCT03630640 |
| Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency |
Unknown status |
Hepatocellular Carcinoma |
NCT01322477 |
| A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT02847377 |
| Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy |
Completed |
Osteosarcoma|Metastasis |
NCT02711007 |
| Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib |
Completed |
Metastatic Renal Cell Carcinoma |
NCT03091465 |
| Vandetanib to Treat Advanced Kidney Cancer |
Terminated |
Advanced Clear Cell Renal Carcinoma |
NCT01372813 |
| ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib |
Active, not recruiting |
Metastatic Kidney Cancers |
NCT03097601 |
| Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) |
Suspended |
Hepatocellular Carcinoma |
NCT01381211 |
| RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC |
Unknown status |
Hepatocellular Carcinoma |
NCT02426450 |
| Sunitinib or Cediranib for Alveolar Soft Part Sarcoma |
Recruiting |
Sarcoma, Alveolar Soft Part |
NCT01391962 |
| A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC) |
Unknown status |
Hepatocellular Carcinoma |
NCT00960167 |
| HR Combined With FOLFOX4 for HCC With PVTT |
Unknown status |
Hepatocellular Carcinoma |
NCT02452853 |
| Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma |
Completed |
Metastatic Colorectal Cancer|Glioblastoma|Bevacizumab|Capillaroscopy |
NCT01810744 |
| Ponatinib for FLT3-ITD Acute Myelogenous Leukemia |
Recruiting |
Acute Myeloid Lukemia |
NCT02428543 |
| Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma |
Completed |
Metastatic Renal Cancer |
NCT02086734 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia |
Recruiting |
Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Mixed Phenotype Acute Leukemia|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Recurrent Mixed Phenotype Acute Leukemia |
NCT02135874 |
| Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients |
Terminated |
Hepatocellular Cancer|Non-small Cell Lung Cancer|Renal Cell Cancer|Colorectal Cancer |
NCT01507740 |
| Tumor Kinase Inhibitor Concentrations Measured by PET |
Completed |
Disseminated Malignant Neoplasm |
NCT02111889 |
| A Phase 2 Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma |
Active, not recruiting |
Advanced Hepatocellular Carcinoma |
NCT03586973 |
| Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer |
Recruiting |
Colorectal Cancer Metastatic |
NCT03251612 |
| Real-world Study for Patients With Advanced Hepatobiliary Tumors |
Recruiting |
Objective Response Rate|Progression-free Survival|Overall Survival|Disease Control Rate|Duration of Response|Five-year Survival Rate|Quality of Life |
NCT03892577 |
| Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN. |
Completed |
Cardiac Complication|Vascular Diseases |
NCT03413176 |
| Ph II Study of Perifosine for Patients With Carcinoma of the Kidney |
Completed |
Kidney Cancer |
NCT00498966 |
| Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Recruiting |
Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer |
NCT03768375 |
| Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies |
Terminated |
Hypertension|Proteinuria |
NCT00698659 |
| A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC |
Terminated |
Triple Negative Breast Cancer|Hepatocellular Carcinoma |
NCT03318562 |
| Paediatric Hepatic International Tumour Trial |
Recruiting |
Hepatoblastoma|Carcinoma, Hepatocellular |
NCT03017326 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Completed |
Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms |
NCT02788201 |
| Study of Iomab-B Prior to Hematopoietic Cell Transplant vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia |
Recruiting |
Acute Myeloid Leukemia|Leukemia, Acute Myeloid|Myeloid Leukemia, Acute|Leukemia, Myeloid, Acute|Acute Myelogenous Leukemia|Leukemia, Acute Myelogenous|Myelogenous Leukemia, Acute|AML|Bone Marrow Transplant |
NCT02665065 |
| A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions |
Not yet recruiting |
Hand-Foot Skin Reaction (HFSR) |
NCT04242927 |
| The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients |
Not yet recruiting |
Hepatocellular Carcinoma |
NCT03511703 |
| The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus |
Not yet recruiting |
Hepatocellular Carcinoma |
NCT03520257 |
| Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. |
Active, not recruiting |
Cancer|Advanced Solid Tumors |
NCT01636908 |
| Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies |
Recruiting |
Leukemia, Acute|MDS |
NCT03680677 |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Recruiting |
Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer |
NCT02836847 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
Completed |
Adenocarcinoma of Colon|Adenocarcinoma of Rectum|Metastatic Disease |
NCT01703910 |
| A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors |
Terminated |
Neoplasms |
NCT00811993 |
| Sutent Rechallenge In mRCC Patients |
Completed |
Metastatic Renal Cell Carcinoma |
NCT01827254 |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) |
Withdrawn |
Leukemia|FLT3-Mutated Acute Myeloid Leukemia|FLT3-Mutated High-Risk Myelodysplastic Syndrome |
NCT02829840 |
| RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma |
Withdrawn |
Renal Cell Carcinoma |
NCT00601120 |
| Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma |
Not yet recruiting |
Melanoma |
NCT02645149 |
| Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer |
Terminated |
Liver Cancer |
NCT01009801 |
| Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma |
Unknown status |
Hepatocellular Carcinoma |
NCT03338166 |
| Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma |
Recruiting |
Renal Cell Carcinoma |
NCT03419572 |
| "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma |
Not yet recruiting |
Hepatocellular Carcinoma |
NCT04317248 |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan |
Completed |
Renal Cell Carcinoma |
NCT02776644 |
| Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging |
Unknown status |
Carcinoma, Hepatocellular|Cirrhosis |
NCT01387503 |
| Tumor Registry of Advanced Renal Cell Carcinoma |
Active, not recruiting |
Renal Cell Carcinoma |
NCT00610012 |
| Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities |
Terminated |
Advanced or Metastatic Solid Malignancy |
NCT01758575 |
| High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
Acute Leukemia of Ambiguous Lineage|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia |
NCT02551718 |
| Temsirolimus-RCC-imaging |
Unknown status |
Renal Cell Cancer |
NCT01246817 |
